6-丁基烟醛 | 181937-07-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-丁基烟醛
• 英文名称: 6-butylnicotinaldehyde
• 英文别名: 6-butylpyridine-3-carbaldehyde
• CAS: 181937-07-5
• 化学式: C₁₀H₁₃NO
• mdl: MFCD18802933
• 分子量: 163.219
• InChiKey: RLPIIZPICZCPKO-UHFFFAOYSA-N

物化性质

• 沸点：
  266.8±20.0 °C(Predicted)
• 密度：
  1.019±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-丁基烟醛 在 哌啶 、 N,N'-二环己基碳二亚胺 作用下， 以 1,4-二氧六环 、 吡啶 为溶剂， 生成
  参考文献：
  名称：

  Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamides

  摘要：

  A new series of 3-(3-pyridyl)acrylamides 16, 17, 19, and 26, and 5-(3-pyridyl)-2,4-pentadienamides 20-25 were prepared and evaluated for their antiallergic activity. Several of these compounds exhibited more potent inhibitory activities than the parent compound 1a [(E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (3-pyridyl)acrylamide] against the rat passive cutaneous anaphylaxis (PCA) reaction and the enzyme 5-lipoxygenase. Particularly, (E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (6-methyl-3-pyridyl)acrylamide (17p) showed an ED50 value of 3.3 mg/kg po in the rat PCA test, which was one-fifth of ketotifen and oxatomide. As compared with ketotifen and oxatomide, compound 17p (AL-3264) possessed a better balance of antiallergic properties due to inhibition of chemical mediator release, inhibition of 5-lipoxygenase, and antagonism of histamine.

  DOI：

  10.1021/jm00123a012
• 作为产物：
  描述：

  Ethyl 6-butylnicotinate 在 lead(IV) acetate 、 红铝 作用下， 以 乙醚 、 甲苯 为溶剂， 生成 6-丁基烟醛
  参考文献：
  名称：

  Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamides

  摘要：

  A new series of 3-(3-pyridyl)acrylamides 16, 17, 19, and 26, and 5-(3-pyridyl)-2,4-pentadienamides 20-25 were prepared and evaluated for their antiallergic activity. Several of these compounds exhibited more potent inhibitory activities than the parent compound 1a [(E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (3-pyridyl)acrylamide] against the rat passive cutaneous anaphylaxis (PCA) reaction and the enzyme 5-lipoxygenase. Particularly, (E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (6-methyl-3-pyridyl)acrylamide (17p) showed an ED50 value of 3.3 mg/kg po in the rat PCA test, which was one-fifth of ketotifen and oxatomide. As compared with ketotifen and oxatomide, compound 17p (AL-3264) possessed a better balance of antiallergic properties due to inhibition of chemical mediator release, inhibition of 5-lipoxygenase, and antagonism of histamine.

  DOI：

  10.1021/jm00123a012

文献信息

• Scalable Negishi Coupling between Organozinc Compounds and (Hetero)Aryl Bromides under Aerobic Conditions when using Bulk Water or Deep Eutectic Solvents with no Additional Ligands
  作者：Giuseppe Dilauro、Claudia S. Azzollini、Paola Vitale、Antonio Salomone、Filippo M. Perna、Vito Capriati

  DOI：10.1002/anie.202101571

  日期：2021.5.3

  Pd‐catalyzed Negishi cross‐coupling reactions between organozinc compounds and (hetero)aryl bromides have been reported when using bulk water as the reaction medium in the presence of NaCl or the biodegradable choline chloride/urea eutectic mixture. Both C(sp3)‐C(sp2) and C(sp2)‐C(sp2) couplings have been found to proceed smoothly, with high chemoselectivity, under mild conditions (room temperature

  当在NaCl或可生物降解的氯化胆碱/尿素低共熔混合物存在下使用大量水作为反应介质时，有机锌化合物与（杂）芳基溴化物之间的钯催化Negishi交叉偶联反应已有报道。C（sp 3）‐C（sp 2）和C（sp 2）‐C（sp 2）已经发现，在空气中的温和条件下（室温或60°C），并与质子分解竞争时，偶联能以高化学选择性平稳地进行。其他好处包括非常短的反应时间（20 s），良好至优异的产率（高达98％），广泛的底物范围以及对各种官能团的耐受性。所提出的新颖协议是可扩展的，并且该方法的实用性通过催化剂和低共熔混合物或水的容易再循环而进一步突出。
• Non-Flushing Niacin Analogues, and Methods of Use Thereof
  申请人：Bachovchin William W.

  公开号：US20090312355A1

  公开（公告）日：2009-12-17

  One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. The present invention also relates to methods of treating a range of mammalian maladies or conditions, including but not limited to hyperlipidemia, hypercholesterolemia, atherosclerosis, coronary artery disease, congestive heart failure, cardiovascular disease, hypertension, coronary heart disease, angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial occlusive disease, obesity, hypothyroidism, vasoconstriction, osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's disease, lipodystrophy, or dyslipidemia, raising serum high-density lipoprotein (HDL) levels, and lowering serum low-density lipoprotein (LDL) levels.

  本发明的一个方面涉及取代吡啶及其药学上可接受的盐，对一系列哺乳动物疾病具有活性。本发明的另一个方面涉及一种制药组合物，包括本发明的化合物或其药学上可接受的盐，以及药学上可接受的载体。本发明还涉及治疗一系列哺乳动物疾病或病症的方法，包括但不限于高脂血症、高胆固醇血症、动脉粥样硬化、冠状动脉疾病、充血性心力衰竭、心血管疾病、高血压、冠心病、心绞痛、糙皮病、哈特努普综合征、类癌综合征、动脉闭塞性疾病、肥胖症、甲状腺功能减退症、血管收缩、骨关节炎、类风湿性关节炎、糖尿病、阿尔茨海默病、脂肪萎缩症或血脂异常，提高血清高密度脂蛋白（HDL）水平，降低血清低密度脂蛋白（LDL）水平。
• NON-FLUSHING NIACIN ANALOGUES, AND METHODS OF USE THEREOF
  申请人：Trustees of Tufts College

  公开号：US20160151343A1

  公开（公告）日：2016-06-02

  One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient. The present invention also relates to methods of treating a range of mammalian maladies or conditions, including but not limited to hyperlipidemia, hypercholesterolemia, atherosclerosis, coronary artery disease, congestive heart failure, cardiovascular disease, hypertension, coronary heart disease, angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial occlusive disease, obesity, hypothyroidism, vasoconstriction, osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's disease, lipodystrophy, or dyslipidemia, raising serum high-density lipoprotein (HDL) levels, and lowering serum low-density lipoprotein (LDL) levels.

  本发明的一个方面涉及取代吡啶及其药学上可接受的盐，对多种哺乳动物疾病具有活性。本发明的另一个方面涉及一种制药组合物，包括本发明的化合物或其药学上可接受的盐；以及药学上可接受的赋形剂。本发明还涉及治疗多种哺乳动物疾病或症状的方法，包括但不限于高脂血症、高胆固醇血症、动脉粥样硬化、冠状动脉疾病、充血性心力衰竭、心血管疾病、高血压、冠心病、心绞痛、糙皮病、哈特努普综合症、类癌综合症、动脉闭塞性疾病、肥胖症、甲状腺功能减退症、血管收缩、骨关节炎、类风湿性关节炎、糖尿病、阿尔茨海默病、脂肪萎缩症或血脂异常，提高血清高密度脂蛋白（HDL）水平，降低血清低密度脂蛋白（LDL）水平。
• ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
  申请人：Leivers Martin Robert

  公开号：US20090197880A1

  公开（公告）日：2009-08-06

  Disclosed are compounds of Formula (I), pharmaceutically acceptable salts and solvates thereof, compositions thereof, and methods for their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.

  本发明涉及公式（I）的化合物，其药学上可接受的盐和溶剂化合物，以及其组合物的制备方法和用于治疗由黄病毒科病毒介导的至少部分病毒感染的用途。
• WO2008/16968
  申请人：——

  公开号：——

  公开（公告）日：——